Impact of Uterotonic Agents on Isolated Human Myometrium

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

Bağlantı panoya saxlanılır

StatusTamamlandı

Sponsorlar

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

KLINIK SINAQ: NCT00989027

BioSeek: nct00989027

Açar sözlər

Mücərrəd

The purpose of this study is to compare the ability of a sample of uterine muscle tissue to contract in the presence of various drugs. The drugs studied are typically used to contract the uterus when a pregnant patient continues to bleed after delivery. Amongst the uterotonic drugs (used to contract the uterus), namely oxytocin, ergonovine and carboprost, the most effective one to use is not known.

The investigators will be testing uterine muscle samples in the presence of these drugs at various concentrations, to see what their contractility measures over time, as compared with a control sample, in which no drugs will be applied.

Təsvir

Postpartum hemorrhage (PPH) is a major cause of maternal mortality and morbidity. In 80% cases of PPH, the primary cause is failure of the uterus to contract after delivery of the baby, which then requires further treatment of the mother with uterotonic drugs (drugs used to contract uterus and thus prevent bleeding).

Patients participating in this study will be asked to donate a very small sample of uterine tissue during Cesarean section, which will be tested for the ability to contract after treatment with various uterotonic drugs (oxytocin, ergonovine and carboprost) in the laboratory. This information will help us know the effect of these drugs by comparing the contractile capability of the uterine tissue.

Tarixlər

Son Doğrulandı:	01/31/2014
İlk təqdim:	07/28/2009
Təxmini qeydiyyat təqdim edildi:	09/30/2009
İlk Göndərmə:	10/01/2009
Son Yeniləmə Göndərildi:	02/18/2014
Son Yeniləmə Göndərildi:	02/19/2014
Həqiqi Təhsilin Başlama Tarixi:	05/31/2007
Təxmini İlkin Tamamlanma Tarixi:	07/31/2013
Təxmini İşin Tamamlanma Tarixi:	07/31/2013

Vəziyyət və ya xəstəlik

Postpartum Hemorrhage

Müdaxilə / müalicə

Drug: Treatment

Faza

Qol Qrupları

Qol	Müdaxilə / müalicə
No Intervention: No treatment A control sample from each patient (no uterotonic drug applied) will be measured concurrently with samples treated with various drugs.
Active Comparator: Treatment Samples from each patient will be bathed in solutions containing varying concentrations of either oxytocin, carboprost and ergonovine, and contractility will be measured.	Drug: Treatment Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

Uyğunluq Kriteriyaları

Təhsilə Uyğun Cinslər

Female

Sağlam Könüllüləri qəbul edir

Bəli

Kriteriyalar

Inclusion Criteria:

- Gestational age 37-41 weeks

- Non-laboring patients, not exposed to exogenous oxytocin

- Patients requiring primary Cesarean section

- Cesarean section under spinal anesthesia

Exclusion Criteria:

- Patients who require general anesthesia

- Patient who had previous uterine surgery or Cesarean section

- Patients with placental anomalies

- Emergency Cesarean section in labor

- Patients with bleeding disorders

Nəticə

İlkin nəticə tədbirləri

1. Amplitude of contraction [6-8 hours]

İkincili Nəticə Tədbirləri

1. Integrated area under response curve (AUC) [6-8 hours]

2. Basal tone [6-8 hours]

3. Frequency of contraction [6-8 hours]